wow.. you have better luck than me. She doesn't call me; but I guess it's ok as long as she is in in good spirits.
Well Roberta is a sweet lady from what I hear and can deduce that she probably got a bunch of real nasty calls last week from irritated investors. I still can't believe they killed all those call options expiring last week. this was a folly of MNKD or today we'd be at 15.
As far as Matt, I just hope he didn't run away and would like him to explain why he thought it would be prudent to go on a holiday right after the biggest announcement in the company's history and why they wouldn't AT least hire a PR person to field all those press calls.
Any CFO knows that wall street hates and I mean HATES uncertainty and that is the reason why MNKD shares got decimated.
Just calling a spade a spade, even though I believe in the company and the end product.
It's called managing the story; spinning the story etc etc.
I worry about those two :)
by borrowing shares, they are keeping the price down to what it should be today!.. $15. Price manipulation.
Nothing to do with the business, which all still believe in, but it is unfair to those people that have spent their hard earned money trying to invest in a business. People then get dejected and leave.. that's what the shorts want.
Case and point --- last week..
in the long camp eh?
Weren't you just last week predicting $5?
don't know what kind of news you are expecting, but I think Mannkind is busy manufacturing their mega blockbuster that Sanofi is eager to market and sell.
Yes I checked Dance. IPO is still not out. They will use the $75 million IPO to conduct their phase 3 studies starting in 2015. That means they don't go commercial until about 2018.
they will need a partner as well.
Their partner will be NOVO or LILY; but SANOFI and MANNKIND will by then be blockbusters or MANNKIND goes bust. If mannkind goes bust, DANCE definitely goes bust.
DANCE could end up becoming 3rd generation of inhale insulin, but it is a long ways off.
They have to go through the SAME hurdles that mannkind just went through to get to commercialization. They even admit this in their S1 filing that mannkind and afrezza has competitive first to market advantage.
I think the "market" is forgetting the potential here. They think the balance sheet is not goo; of course it won't be. They have been an R&D company about to go commercial with the BEST diabetes marketer int he world (GLOBAL) in Sanofi AND.... with NO competition, REPEAT NO COMPETITION (inhaled insulin) coming in the next few years!!
I think it's above 10, won't happen till every short covers... sigh..
but it's ok, because the product will indeed be a blockbuster.